{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:14:41Z","timestamp":1781748881166,"version":"3.54.5"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5191-24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:46Z","timestamp":1744394986000},"page":"3007-3011","source":"Crossref","is-referenced-by-count":4,"title":["Obinutuzumab-induced Acute Thrombocytopenia Mimicking Immune Thrombocytopenia in a Patient with Follicular Lymphoma"],"prefix":"10.2169","volume":"64","author":[{"given":"Misato","family":"Tane","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hosoi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Japan"},{"name":"Department of Transfusion Medicine, Wakayama Medical University Hospital, Japan"},{"name":"Department of Internal Medicine, Kainan Municipal Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hiroi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kainan Municipal Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Mushino","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Japan"},{"name":"Department of Transfusion Medicine, Wakayama Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182: 29-45, 2018.","DOI":"10.1111\/bjh.15232"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377: 1331-1344, 2017.","DOI":"10.1056\/NEJMoa1614598"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mechelfekh Y, Pontrucher A, Paillassa J, Temple M, Houot R. Obinutuzumab-induced acute thrombocytopenia: report of two cases and review of literature. Br J Haematol 202: 168-172, 2023.","DOI":"10.1111\/bjh.18826"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Omura Y, Shimazu H, Takahashi T. Rituximab-induced acute thrombocytopenia in a patient with follicular lymphoma: a case report and review of the literature. Intern Med 57: 1151-1154, 2018.","DOI":"10.2169\/internalmedicine.9628-17"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ng JY, Joshi M, Choi P. Frequency and outcomes of obinutuzumab-induced thrombocytopenia. Br J Haematol 203: 668-672, 2023.","DOI":"10.1111\/bjh.19147"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sakuragi M, Hayashi S, Maruyama M, et al. Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol 101: 369-375, 2015.","DOI":"10.1007\/s12185-015-1741-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kashiwagi H, Kuwana M, Murata M, et al. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition. Int J Hematol 119: 1-13, 2024.","DOI":"10.1007\/s12185-023-03672-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 281: 1208-1212, 1969.","DOI":"10.1056\/NEJM196911272812202"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med 114: 322-325, 2003.","DOI":"10.1016\/S0002-9343(02)01522-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kuwana M, Okazaki Y, Ikeda Y. Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia. PLoS One 9: e86943, 2014.","DOI":"10.1371\/journal.pone.0086943"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370: 1101-1110, 2014.","DOI":"10.1056\/NEJMoa1313984"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17: 1081-1093, 2016.","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol 35: 3529-3537, 2017.","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Walter HS, Jayne S, Mensah P, Miall FM, Lyttelton M, Dyer MJ. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12. Blood Cancer J 6: e435, 2016.","DOI":"10.1038\/bcj.2016.42"},{"key":"15","unstructured":"15. Sakai K, Matsumura T, Hamada R, Tominaga T, Takahashi T. Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma. Rinsho Ketsueki (Jpn J Clin Hematol) 61: 1616-1619, 2020 (in Japanese)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Haage TR, Surov A, Mougiakakos D, Berisha M. Successful use of intravenous immunoglobulins in an obinutuzumab-related acute thrombocytopenia. Hemasphere 6: e751, 2022.","DOI":"10.1097\/HS9.0000000000000751"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fujiwara Y, Urata T, Niiya D, et al. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group. Int J Hematol 115: 811-815, 2022.","DOI":"10.1007\/s12185-022-03363-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Y\u0131lmaz U, K\u00fc\u00e7\u00fckyurt S, Ar MC, E\u015fkazan AE. Acute thrombocytopenia complicating the initial administration of obinutuzumab: is it more frequent than we think? Oncol Ther 12: 157-161, 2024.","DOI":"10.1007\/s40487-023-00259-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program 2018: 576-583, 2018.","DOI":"10.1182\/asheducation-2018.1.576"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 357: 580-587, 2007.","DOI":"10.1056\/NEJMra066469"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica 107: 1264-1277, 2022.","DOI":"10.3324\/haematol.2021.279484"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 16: 620-632, 2017.","DOI":"10.1016\/j.autrev.2017.04.012"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Liu Q, Liu Y. Role of IL-10 and IL-22 cytokines in patients with primary immune thrombocytopenia and their clinical significance. J Clin Lab Anal 36: e24573, 2022.","DOI":"10.1002\/jcla.24573"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Luke N, Pierce K, Hillier K. Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease. Eur J Haematol 113: 384-385, 2024.","DOI":"10.1111\/ejh.14262"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 126: 2646-2649, 2015.","DOI":"10.1182\/blood-2015-09-670802"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lujan JV, Lengerke-Diaz PA, Jacobs C, et al. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica 105: e22-e25, 2020.","DOI":"10.3324\/haematol.2018.212597"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Greil R, Tedeschi A, Moreno C, et al. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Ann Hematol 100: 1733-1742, 2021.","DOI":"10.1007\/s00277-021-04536-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R. Obinutuzumab-related adverse events: a systematic review and meta-analysis. Hematol Oncol 39: 215-221, 2021.","DOI":"10.1002\/hon.2828"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5191-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:33Z","timestamp":1760761653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5191-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":28,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5191-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5191-24"}}